Payment overview · 2025
General Payments
$273.10
13 reported records · 6 companies
Healthcare provider profile · identity verified
Elio M Vento, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELGIN, IL · NPI 1487717492
Verified facts
What the public records show
CMS Open Payments records show Elio M Vento, M.D. received $273.10 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 34.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 627 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Genotropin by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.56 | 34.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.41 | 30.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.39 | 12.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.22 | 9.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.10 | 7.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.42 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.10 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $77.64 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $6.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $6.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 627 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
627 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1514 | 311 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1293 | 258 |
| Potassium Chloride | Potassium Chloride | 775 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 673 | 156 |
| Metoprolol Succinate | Metoprolol Succinate | 668 | 162 |
| Gabapentin | Gabapentin | 653 | 123 |
| Omeprazole | Omeprazole | 649 | 167 |
| Eliquis | Apixaban | 627 | 85 |
| Furosemide | Furosemide | 516 | 112 |
| Metformin Hcl | Metformin Hcl | 516 | 127 |
| Losartan Potassium | Losartan Potassium | 512 | 123 |
| Metoprolol Tartrate | Metoprolol Tartrate | 500 | 109 |
| Lisinopril | Lisinopril | 446 | 107 |
| Sertraline Hcl | Sertraline Hcl | 433 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 428 | 101 |
| Warfarin Sodium | Warfarin Sodium | 421 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 378 | 89 |
| Simvastatin | Simvastatin | 328 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 300 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 288 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 87 |
| Carvedilol | Carvedilol | 270 | 68 |
| Allopurinol | Allopurinol | 249 | 56 |
| Trazodone Hcl | Trazodone Hcl | 222 | 40 |
| Bumetanide | Bumetanide | 214 | 47 |
| Xarelto | Rivaroxaban | 214 | 32 |
| Memantine Hcl | Memantine Hcl | 198 | 29 |
| Donepezil Hcl | Donepezil Hcl | 186 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 186 | 37 |
| Jardiance | Empagliflozin | 185 | 42 |
| Azithromycin | Azithromycin | 184 | 150 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 43 |
| Montelukast Sodium | Montelukast Sodium | 174 | 33 |
| Mirtazapine | Mirtazapine | 172 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 159 | 42 |
| Levetiracetam | Levetiracetam | 158 | 22 |
| Tramadol Hcl | Tramadol Hcl | 151 | 47 |
| Alprazolam | Alprazolam | 148 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 36 |
| Famotidine | Famotidine | 130 | 29 |
| Nifedipine Er | Nifedipine | 128 | 21 |
| Atenolol | Atenolol | 127 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 127 | 89 |
| Prednisone | Prednisone | 123 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 37 |
| Alendronate Sodium | Alendronate Sodium | 119 | 27 |
| Myrbetriq | Mirabegron | 119 | 13 |
| Spironolactone | Spironolactone | 119 | 32 |
| Januvia | Sitagliptin Phosphate | 118 | 18 |
| Lovastatin | Lovastatin | 118 | 29 |
| Baclofen | Baclofen | 117 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 115 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 113 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 106 | 46 |
| Ezetimibe | Ezetimibe | 103 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 102 | 12 |
| Glipizide Er | Glipizide | 102 | 29 |
| Meloxicam | Meloxicam | 98 | 24 |
| Risperidone | Risperidone | 97 | 15 |
| Finasteride | Finasteride | 93 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 86 | 13 |
| Lorazepam | Lorazepam | 84 | 27 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 83 | 17 |
| Ozempic | Semaglutide | 83 | 17 |
| Enalapril Maleate | Enalapril Maleate | 81 | 19 |
| Glipizide | Glipizide | 81 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 24 |
| Vancomycin Hcl | Vancomycin Hcl | 79 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 19 |
| Gentamicin Sulfate | Gentamicin Sulfate | 73 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 21 |
| Sucralfate | Sucralfate | 73 | 13 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Glimepiride | Glimepiride | 70 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 18 |
| Entresto | Sacubitril/Valsartan | 63 | 12 |
| Latanoprost | Latanoprost | 63 | 14 |
| Farxiga | Dapagliflozin Propanediol | 62 | suppressed |
| Gemfibrozil | Gemfibrozil | 60 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 36 |
| Cephalexin | Cephalexin | 58 | 32 |
| Celecoxib | Celecoxib | 57 | 15 |
| Nystatin | Nystatin | 57 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 34 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 46 | 12 |
| Digoxin | Digoxin | 45 | suppressed |
| Enulose | Lactulose | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | 20 |
| Valsartan | Valsartan | 44 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 43 | 18 |
| Bethanechol Chloride | Bethanechol Chloride | 42 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Nyamyc | Nystatin | 36 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 36 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 21 |
| Enoxaparin Sodium | Enoxaparin Sodium | 34 | suppressed |
| Genotropin | Somatropin | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 25 |
| Fluconazole | Fluconazole | 33 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 16 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 12 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 12 |
| Imipramine Hcl | Imipramine Hcl | 30 | suppressed |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Clozapine | Clozapine | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | 12 |
| Topiramate | Topiramate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Nateglinide | Nateglinide | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 16 |
| Clotrimazole | Clotrimazole | 22 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 21 | 18 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | 11 |
| Humulin N | Insulin Nph Human Isophane | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Daptomycin | Daptomycin | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Nystop | Nystatin | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Probenecid | Probenecid | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.10 · 13 records | Novo Nordisk Inc | ELIQUIS, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, SYNTHROID, UBRELVY, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error